October 18, 2023 — DeepTek.ai, a leading medical imaging AI company in India has announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its revolutionary Chest X-ray AI solution - CXR Analyzer. This advanced technology uses deep learning algorithms to detect abnormalities in chest X-rays. It identifies, categorizes, and highlights suspicious areas automatically, aiding clinicians in making precise interpretations.
Unlike traditional point AI solutions identifying a specific pathology, DeepTek's Chest X-ray AI covers the entire chest area, offering analysis for a broad range of lung, pleural, cardiac pathologies and foreign bodies/hardware on the chest. It's compatible with various X-ray machines, including hospital-based, mobile, portable, hand-held, and ultra-portable units making it versatile and powerful.
This AI model accelerates decision-making by detecting and locating suspicious lesions in chest X-rays, which are crucial for diagnosing conditions like lung infections, cancer, and chronic lung diseases. In a world with 3.5 billion annual X-rays, 1.5 billion are chest X-rays, making the need for precise interpretation essential. The shortage of radiologists further emphasizes the role of AI in addressing this challenge.
Dr. Amit Kharat, Co-Founder of DeepTek.ai, quoted "DeepTek CXR Analyzer v1.0 is a game-changer, reducing radiologist workload by an impressive 30-50%. With FDA clearance, we're not only accessing the vast US healthcare market but also impacting lives globally. By swiftly identifying lung abnormalities and offering precise mapping, we're unlocking a world of possibilities for improved outcomes across various medical specialties."
DeepTek's AI solutions have been transforming healthcare in India and the Asia-Pacific region by providing increased access to quality care at a lower cost. Over 500 hospitals and imaging centers are using DeepTek's AI solutions, impacting the lives of 100,000 people monthly. More than half a million people have been screened using DeepTek's Chest X-Ray Analyzer for tuberculosis screening. In Singapore, DeepTek's US FDA approved Platform - Augmento has been deployed as the National Radiology AI platform, boosting productivity and quality of care across all public hospitals.
With its operations in Pune; DeepTek has about 200 members and has partners like TATA Capital, NTT DATA Japan and Shimadzu Asia Pacific.
For more information, visit : www.deeptek.ai
March 10, 2026 
